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on potency and toxicity. Furthermore, reference values and information on postmortem redistribution
(PMR) do not exist so far for most NPS. A fatal case involving the amphetamine-derivatives MDAI (5,6-
methylenedioxy-2-aminoindane) and 2-MAPB (1-(benzofuran-2-yl)-N-methylpropan-2-amine) was inves-
tigated at the Zurich Institute of Forensic Medicine. At admission at the institute approx. 11 h after
death (first time point, t1), femoral and heart blood (right ventricle) was collected using computed to-
mography (CT)-guided biopsy sampling. At autopsy (t2), samples from the same body regions as well as
various tissue samples were collected manually. In addition, an antemortem blood sample collected 6 h
before death was available. MDAI and 2-MAPB were quantified using a validated LC–MS/MS method.
A significant concentration decrease between the antemortem and the first peripheral postmortem blood
sample was observed, which most probably can be explained by remaining metabolism and excretion
within the last 6 h prior to death. No significant concentration change was observed between the two
postmortem heart blood and peripheral blood samples. Accordingly, MDAI and 2-MAPB did not seem
to undergo relevant postmortem redistribution in peripheral and heart blood in the presented case. This
is the first study on postmortem redistribution of the new psychoactive substances MDAI and 2-MAPB.
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Intoxication cases involving new psychoactive substances (NPS) provide several challenges for forensic 
toxicologists as data on pharmacodynamic and pharmacokinetic properties are lacking, especially on potency 
and toxicity. Furthermore, reference values and information on postmortem redistribution (PMR) do not exist so 
far for most NPS. A fatal case involving the amphetamine-derivatives MDAI (5,6-methylenedioxy-2-
aminoindane) and 2-MAPB (1-(benzofuran-2-yl)-N-methylpropan-2-amine) was investigated at the Zurich 
Institute of Forensic Medicine. At admission at the institute approx. 11 h after death (first time point, t1), 
femoral and heart blood (right ventricle) was collected using computed tomography (CT)-guided biopsy 
sampling. At autopsy (t2), samples from the same body regions as well as various tissue samples were collected 
manually. In addition, an antemortem blood sample collected 6 hours before death was available. MDAI and 2-
MAPB were quantified using a validated LC-MS/MS method. A significant concentration decrease between the 
antemortem and the first peripheral postmortem blood sample was observed, which most probably can be 
explained by remaining metabolism and excretion within the last 6 hours prior to death. No significant 
concentration change was observed between the two postmortem heart blood and peripheral blood samples. 
Accordingly, MDAI and 2-MAPB did not seem to undergo relevant postmortem redistribution in peripheral and 
heart blood in the presented case. This is the first study on postmortem redistribution of the new psychoactive 
substances MDAI and 2-MAPB. However, more studies covering more cases are necessary to generate 
universal statements on the PMR with these two NPSs. 
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MDAI (5,6-methylenedioxy-2-aminoindane) and 2-MAPB (1-(benzofuran-2-yl)-N-methylpropan-2-amine) 
belong to the class of new psychoactive substances (NPS). Both analytes are serotonin-releasing agents and 
appear to have comparable pharmacological effects to MDA and MDMA, but seem to act rather sedative than 
stimulative [1, 2]. In rodents, MDAI fully substituted for the discriminative-stimulus effects of MDMA [3]. A 
study in mice investigated the effect of benzofurans and MDMA on the monoamine levels in the mouse corpus 
striatum. 2-MAPB increased serotonin and dopamine concentrations to the same extent as MDMA, the 
concentration increase of noradrenaline caused by 2-MAPB, however, was smaller compared to MDMA [2]. To 
date, only few forensic case reports involving MDAI are available [1]. To the best of our knowledge, no case 
reports involving 2-MAPB have been published. However, several case reports involving other benzofurans 
such as 5-APB, 6-APB or 5-MAPB were described [4-8]. In general, NPS are an emerging problem in forensic 
toxicology with many intoxication cases reported [9]. Such intoxication cases involving NPS provide several 
challenges for forensic toxicologists as data on pharmacodynamic and pharmacokinetic properties are lacking, 
especially on potency and toxicity. Furthermore, interpretation of (postmortem) blood concentrations is difficult, 
as also reference values and information on postmortem redistribution (PMR) of these analytes do not exist so 
far. PMR complicates interpretation of forensic death cases with drugs involved. Several mechanisms such as 
e.g. drug degradation, new formation or diffusion processes can contribute to PMR and are believed to be time-
dependent [10]. Data on time-dependent PMR is generally rare and mainly exists for classical drugs such as 
opiates, benzodiazepines, antidepressants or antipsychotics [11-13]. PMR of NPS can only be assumed based on 
structural similarities to known substances or estimated based on their physicochemical properties such as e.g. 
lipophilicity or pKa. Structural similarity especially of MDAI to MDMA suggests comparable postmortem 
behavior to amphetamines. Elliot et al. compared postmortem to antemortem MDMA and MDA concentrations 
and found the postmortem concentrations to be higher in all cases [14]. Gerostamoulos et al. observed 
postmortem concentration decreases for amphetamine and methamphetamine; however, they were not 
significant [11]. The aim of this work was to investigate tissue distribution and time-dependent PMR of MDAI 
and 2-MAPB in a single authentic case. 
Case history  
A 27-year old male was found in his bed with a respiratory arrest around 6.50 pm. His wife started resuscitation 
immediately. The ambulance diagnosed a cardiac arrest and initiated defibrillation including administration of 
adrenaline, heparin and acetylsalicylic acid with return of spontaneous circulation 40 minutes later. 
Additionally, flumazenil and naloxone were injected. The pupils were dilated with no reaction to light. Shortly 
after hospitalization, a second resuscitation was necessary with return of spontaneous circulation 40 minutes 
later. The blood-gas analysis revealed a severe mixed respiratory-metabolic acidosis with a pH of 6.8, 
hyperpotassemia of 6.5 mmol/L and hypoglycemia of 2.9 mmol/L. Heart-enzymes, liver enzymes and kidney 
retention values were elevated. No other striking clinical symptoms were observed including unremarkable 
computer tomography (CT) of the cranium, thorax and the abdomen. The patient died the next day at 2.47 am 
(i.e. around 8 h after he had been found in bed). Postmortem autopsy revealed a massive edema of the brain, 
aspiration pneumonia with lung edema and acutely blood congested internal organs as unspecific intoxication 
signs. According to his wife he had been an opioid user and had consumed “a handful of” hydromorphone, an 
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ecstasy derivative and possibly some tramadol two days ago. He had been asleep the whole previous day, 
unresponsive but always breathing. The night before, he had had nightmares and was snoring.  
Material and methods 
Chemicals and reagents 
An acetonitrilic solution (1 mg/mL) of MDAI was obtained from Sigma-Aldrich Chemie GmbH (Buchs, 
Switzerland), a methanolic solution (1 mg/mL) of 2-MAPB from Adipogen AG (Liestal, Switzerland) and a 
methanolic solution (1 mg/mL) of MDMA-d5 from Lipomed AG (Arlesheim, Switzerland). Water was purified 
with a Purelab Ultra millipore filtration unit (Labtech, Villmergen, Switzerland), acetonitrile of HPLC grade 
was obtained from Fluka (Buchs, Switzerland) and all other chemicals used were obtained from Merck (Zug, 
Switzerland). 
Antemortem samples 
Antemortem samples were collected during hospitalization and delivered to the institute of forensic medicine for 
further investigation. A urine sample was collected 5.5 hours before death and a blood sample 6 hours before 
death (t0). 
Postmortem samples 
Blood and alternative matrices were collected at two time points t1 and t2 after death according to Staeheli et al. 
[15]. Briefly, after the routine CT imaging procedure (t1, 11 hours after death) on a 128-slice scanner (Somatom 
Definition Flash, Siemens Medical Solutions, Forchheim, Germany), introducer needles were placed into the 
right heart ventricle, the right lung, the right lobe of the liver, the spleen, subcutaneous adipose tissue of the 
waist, muscle tissue at the upper left thigh and the right femoral vein using the virtobot system. After placement 
of the introducer needles, another CT scan was performed to confirm the needle positions. From the right heart 
ventricle and the femoral vein, 1 mL blood was collected using a 5 mL syringe. The body fluids were aliquoted 
in triplicates of 20 µL into 2 mL Eppendorf Safe Lock Tubes (Schoenenbuch, Switzerland). The following day 
at autopsy (t2, 29 hours after death), samples from the same locations were collected where biopsies had been 
taken at t1. Additionally, heart blood from the left ventricle, heart muscle tissue from the left ventricle, 
cerebellum, frontal lobe and gastric content were collected. Urine was not available. After autopsy, the solid 
matrices were aliquoted into triplicates of approx. 20 mg and body fluids into triplicates of 20 µL. All samples 
were stored at -20 °C until analysis.  
Sample preparation 
Extraction of tissue and body fluid samples were performed according to Staeheli et al. [16]. Briefly, organ and 
tissue samples were homogenized using a Fast Prep®-24 Instrument (MP Biomedicals, Illkirch, France). Two 
liquid-liquid extractions (LLE) with butyl acetate/ethyl acetate (1:1, v/v) were performed, one at pH 7.4 and one 
at pH 13.5. The extracts were combined, evaporated to dryness and reconstituted in 60 µL mobile phase.  
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Routine systematic toxicological analysis 
Routine toxicological analysis was performed with blood and urine collected 6 hours before death and with the 
blood sample collected at autopsy 29 hours after death. Urine was screened initially by a cloned enzyme donor 
immunoassay (CEDIA®) for drugs of abuse (opiates, cocaine, cannabis, amphetamines, methadone, 
barbiturates, benzodiazepines, and lysergic acid diethylamide (LSD)), followed by an untargeted LC-MS/MS 
ion trap screening after simple protein precipitation (Bruker amazon®, Maurer/Wissenbach/Weber database 
[17]) and for ethanol and other volatile compounds by headspace GC flame ionization detector (HD-GC-FID). 
Quantification of drugs in peripheral blood was performed by LC-MS/MS.  
LC-MS/MS analysis of MDAI and 2-MAPB 
The quantitative analysis was performed using a Thermo Fischer Ultimate 3000 UHPLC system (Thermo 
Fisher, San Jose, California, USA) coupled to a Sciex 5500 QTrap linear ion trap quadrupole mass spectrometer 
(Sciex, Darmstadt, Germany). The MS was operated in the unscheduled multiple reaction monitoring (MRM) 
mode using six transitions for MDAI and 2-MAPB each. Three transitions corresponded to the 12C isotope and 
three transitions corresponded to the 13C isotope of MDAI and 2-MAPB, respectively. Quantifier transitions for 
MDAI and its 13C isotope were 178→103 and 179→104, respectively. Quantifier transitions for 2-MAPB and 
its 13C isotope were 190→91 and 191→92, respectively. MDMA-d5 was used as internal standard (IS). 
Remaining MS settings were according to Staeheli et al. [16]. An LC gradient elution was performed using a 
Phenomenex (Aschaffenburg, Germany) Synergy Polar RP column (100 x 2.0 mm, 2.5 µm) with 10 mM 
ammonium formate buffer in water containing 0.1% (v/v) formic acid (pH 3.5, eluent A) and acetonitrile 
containing 0.1% (v/v) formic acid (eluent B) according to Staeheli et al. [16]. The MS was controlled by 
Analyst® 1.6.2 software (Sciex) and quantitation was performed with MultiQuant® 2.1.1 software (Sciex). 
MDAI and 2-MAPB concentrations in urine were calculated using the 13C calibration. Concentrations of all 
other samples were calculated with the 12C calibration.  
Significance of concentration change between t0, t1 and t2 was investigated applying a paired Student`s t-test 
(p<0.05) using GraphPad Prism 6. The concentration ratios between the different matrices and peripheral blood 
were calculated for t1 and t2. 
 
LC-MS/MS method validation 
The method was validated in terms of selectivity, matrix effects, accuracy, precision, calibration model and 
limits in postmortem femoral blood according to Peters et al. [18]. 
Selectivity 
Six blank postmortem blood samples from different sources and two blank postmortem blood samples spiked 
with IS (zero samples) were analyzed for interfering peaks with MDAI and 2-MAPB. Selectivity regarding 
other drugs was investigated injecting a methanolic solution containing a mixture of drugs of abuse, 
benzodiazepines, antidepressant, neuroleptics and opioids in the concentration of QC high according to Staeheli 




Eight calibrators were prepared in duplicates at concentrations 5, 25, 100, 200, 500, 1000, 2500, 5000 and 7500 
ng/mL. For calibrators 1-5 (1-1000 ng/mL), the 12C isotopes of MDAI and 2-MAPB were used as quantifiers. 
For calibrators 4-8 (500-7500 ng/mL) the 13C isotopes were used as quantifiers. The regression lines for both 
calibrations 12C and 13C were calculated using a simple linear model with 1/X weighting. Back calculation of the 
calibrator concentrations should result in less than ± 20% bias to the theoretical concentration.  
Accuracy and precision 
Six replicates of quality control (QC) samples at the concentrations levels QC low (7.5 ng/mL), QC med (550 
ng/mL) and QC high (6000 ng/mL) were analyzed each on the same day. Concentration of QC low was 
calculated using 12C calibration (5-1000 ng/mL) and the concentration of QC high was calculated using 13C 
calibration (500-7500 ng/mL). QC med concentration was determined with both calibrations. Accuracy was 
calculated as the percent deviation of the mean calculated concentration at each concentration level from the 
corresponding theoretical concentration. Precision was calculated as the relative standard deviation (RSD) 
within the QC levels. 
Matrix effect and extraction efficiency 
Matrix effect and extraction efficiency were investigated with six blank postmortem blood samples from 
different sources at the concentrations levels of QC med according to Peters et al. [18].  
Limits 
The limit of quantitation (LOQ) was defined as the concentration of the lowest calibrator (5 ng/mL) fulfilling 
the criteria of signal to noise 10:1 and back-calculated concentrations within +/- 20% of target. The limit of 
detection (LOD) was not systematically investigated.  
Results and discussion 
Routine systematic toxicological analysis 
CEDIA® immunoassays in urine were positive for opiates and amphetamines. The LC-ion trap MS screening in 
urine revealed diphenhydramine. Analysis for detection of NPS in urine was performed at the Institute of 
Forensic Medicine Freiburg, Germany and identified MDAI and 2-MAPB (Fig. 1). Quantitative analysis in the 
Zurich Institute of Forensic Medicine (ZIFM) in peripheral blood collected 6 hours before death resulted in 180 
µg/L diphenhydramine, and gave negative results for amphetamine, methamphetamine, MDMA, MDEA, 
opiates and tramadol. Quantitative analysis in peripheral blood collected 29 hours after death revealed 78 µg/L 
morphine. Due to the lack of morphological findings able to explain death, an intoxication was discussed as the 
most likely cause of death. However, because of the possibly rather long agonal phase of up to two days, it 
remained unclear which substances finally contributed to the intoxication. Corkery et al. observed toxic effects 
of MDAI in the mg/L range [1]. No case reports involving 2-MAPB are available to date. However, for other 
benzofurans toxic effects were also observed to be in the mg/L range [4, 5]. Therefore, despite the suspected 
long agonal phase, the concentrations of MDAI and 2-MAPB rather seemed to be too low to be responsible for 
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death. Next to the amphetamine derivatives and diphenhydramine, other drugs such as opioids might have been 
involved, which were not detectable anymore at time of hospitalization in blood or urine. 
MDAI and 2-MAPB analysis 
A short one day method validation was performed for MDAI and 2-MAPB in postmortem blood as proposed by 
Peters and Drummer for analysis of rarely occurring compounds [18]. No interfering peaks were detected in the 
blank postmortem blood samples, the zero samples and in the QC high sample containing a mixture of other 
drugs. For both 12C and 13C calibration a linear regression model with 1/X weighting was used. 13C calibration 
was used to extend the dynamic range of the method. Concentrations in tissues often exceed blood 
concentrations to several magnitudes, which demands for a wide dynamic range [15, 19, 20]. Inclusion of the 
13C isotope as a quantifier allowed analysis of low and high concentrations using the same sample preparation 
and analytical method [16, 21]. Validation results including accuracy, precision, matrix effects and extraction 
efficiency are given in Table 1. Validation exclusively in blood is of course generally not sufficient to evaluate 
the method performance in other matrices such as postmortem tissues. However, the analytes were included in 
an already existing method for 83 drugs validated in 11 different postmortem matrices, which was developed to 
investigate postmortem redistribution of various drugs. In our opinion it is essential to know the distribution of a 
drug to be able to investigate and interpret its postmortem redistribution. Therefore, the aim was to investigate a 
large number of matrices. The former validation had shown that accuracy and precision of the applied method 
was within the required ranges for the majority of the analytes in most matrices as long as an IS had been used 
[16]. Only 2-MAPB QC med precision exceeded the required limit minimally, which was considered as 
acceptable due to analysis of triplicate samples in the case investigation. Comparison between time points was 
performed in a relative manner anyway. Therefore, validation only in postmortem blood was chosen as a 
compromise between extensive method validation and significance of the expected findings and the resulting 
accuracy and precision were considered as acceptable. 
MDAI and 2-MAPB concentrations at autopsy are displayed in Fig. 2 and Fig. 3, respectively. Both analytes 
were highest concentrated in gastric content, followed by liver and lung tissue. The high concentrations in 
gastric content could be explained by oral intake followed by trapping of the basic compounds in the acidic 
compartment or redistribution into the gastric content. In addition, the gastrointestinal transit might have been 
inhibited as the person was stated to be an opioid user. High concentrations in liver and lung tissue are often 
observed for weak bases and could be explained by lysosomal trapping and the high perfusion rate of the organs 
[22, 23]. Concentrations in heart blood tended to be slightly higher compared to peripheral blood, especially for 
2-MAPB. This concentration difference might have been caused by redistribution from the heart muscle by 
diffusion or from the lung tissue by transport along the pulmonary veins. Lowest concentrations were found in 
adipose tissue, which was not surprising as the amphetamine derivatives are rather hydrophilic molecules. A 
urine sample was available only for t0 (antemortem) and contained 1800 µg/L MDAI and 2100 µg/L 2-MAPB. 
No data on the distribution of MDAI and 2-MAPB within the body was available so far, but found to be 
comparable to the distribution of MDMA [24, 25].  
Time-dependent concentration changes of MDAI and 2-MAPB are displayed in Fig. 4. A significant 
concentration decrease between the antemortem and the first peripheral postmortem blood sample was observed. 
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Postmortem redistribution is believed to occur in the first minutes to hours after death [26]. However, the 
concentration decrease in the presented case can most probably be explained by remaining metabolism and 
excretion within the last 6 hours before death. Nevertheless, concentration decrease between death and the first 
postmortem sampling time point t1 cannot be totally excluded, as the concentrations at time of death are 
unknown. Furthermore, a concentration difference due to comparison of the two different matrices plasma (t0) 
and whole blood (t1) cannot be excluded. However, blood-to-plasma factors of amphetamines mostly range 
between 0.7 and 1.3 [24], and are therefore expected to be in the same rather low range for MDAI and 2-MAPB. 
In addition, stability of the two analytes in postmortem matrices has not been investigated. Therefore, it cannot 
be excluded that analyte stability contributed to the concentration change between t0 and t1. No significant 
concentration change was observed between the two postmortem heart blood and peripheral blood samples. In 
summary, MDAI and 2-MAPB did not seem to undergo relevant postmortem redistribution in peripheral and 
heart blood in the presented case.  
Conclusions 
A fatal case involving MDAI and 2-MAPB was investigated for postmortem distribution and redistribution of 
the two analytes. Distribution of the two analytes was comparable to the distribution of MDMA. No significant 
postmortem concentration changes for MDAI and 2-MAPB were observed in peripheral and heart blood. 
Therefore, MDAI and 2-MAPB did not seem to undergo postmortem redistribution in the presented case. 
However, more studies covering more cases are necessary to generate universal statements on the PMR with 
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Table 1 LC-MS/MS method validation results for MDAI and 2-MAPB (matrix effects and extraction 



























low -19.6 8.8         
med 0.0 6.0 84 ± 4 88 ± 6 93 ± 13 112 ± 2 
13C 
med -21.0 8.7 89 ± 5 94 ± 6 87 ± 13 105 ± 3 
high -1.4 8.4         
MDAI 
12C 
low 2.2 -5.2         
med 3.5 -13.3 78 ± 7  81 ± 9 99 ± 5 113 ± 5 
13C 
med 9.4 -13.3 80 ± 10 82 ± 15 98 ± 2 109 ± 5 














Figure 3 2-MAPB mean concentrations and ranges of triplicate measurements at autopsy (t2) 
 
 
Figure 4 MDAI and 2-MAPB mean concentrations and ranges of triplicate measurements in peripheral blood 
(PB) collected 6 hours before death at hospital (t0), as well as peripheral blood (PB) and heart blood (HB) 
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